RVNC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2022 in the Class Action Filed on Behalf of Revance Therapeutics, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - January 24, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) alleging that the Company violated federal securities laws.
Class Period: November 25, 2019 to October 11, 2021
Lead Plaintiff Deadline: February 8, 2022
No obligation or cost to you.
Learn more about your recoverable losses in RVNC:
Revance Therapeutics, Inc. NEWS - RVNC NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Revance Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) quality control deficiencies existed at the Company's manufacturing facility for DaxibotulinumtoxinA for Injection ("DAXI"); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration ("FDA") would approve the DAXI Biologics License Application ("BLA") in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Revance you have until February 8, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Revance securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111416